DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

[Vitamin K2 as a potential therapeutic agent for glucocorticoid-induced osteoporosis]

Author(s): Tanaka I, Oshima H

Affiliation(s): Fujita Health University, Department of Clinical and Laboratory Medicine.

Publication date & source: 2007-11, Clin Calcium., 17(11):1738-44.

Publication type: English Abstract; Review

In recent years, bone quality is thought to be an important factor in bone strength. Vitamin K(2) (VK(2))drugs inhibit bone fracture, although their effect of increasing bone mineral density (BMD)is lower compared to bisphosphonate. This suggests VK(2) analogs improve bone quality. Glucocorticoid-induced osteoporosis(GIOP)brings about a bone fracture even under the condition of high BMD. VK(2) drugs might be effective to prevent bone fracture in GIOP, because they increase bone strength independently of bone mineral density (BMD).

Page last updated: 2008-03-26

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017